Granulosa cells in the ovulatory follicle express messenger ribonucleic acid encoding vascular endothelial growth factor (VEGF), an agent that may mediate the neovascularization of the developing corpus luteum, but it is not known whether luteinizing granulosa cells synthesize and secrete VEGF during the periovulatory interval. Studies were designed to evaluate the effects of an in vivo gonadotropin surge on VEGF production by macaque granulosa cells (study 1) and to test the hypothesis that gonadotropins act directly on granulosa cells to regulate VEGF production (study 2). Monkeys received a regimen of exogenous gonadotropins to promote the development of multiple preovulatory follicles. Nonluteinized granulosa cells (i.e. preovulatory; NLGC) and luteinized granulosa cells (i.e. periovulatory; LGC) were aspirated from follicles before and 27 h after an ovulatory gonadotropin bolus, respectively. Cells were either incubated for 24 h in medium with or without 100 ng/mL hCG (study 1) or cultured for 6 days in medium with or without 100 ng/mL hCG or 0.1, 1, 10, and 100 ng/mL of recombinant human LH (r-hLH) or r-hFSH (study 2).
D
URING THE primate ovarian cycle, a single dominant follicle is selected from a cohort of growing antral follicles to mature and, in response to the midcycle gonadotropin surge, to ovulate and subsequently luteinize to form the corpus luteum (1, 2) . Significant changes in follicular vascularity are associated with the growth process, including 1) greater microvascular perfusion, 2) increased capillary density in the theca interna, and 3) enhanced capillary permeability (3) (4) (5) (6) . Indirect evidence suggests that the selection process occurs as a result of increased perfusion of the dominant follicle to the detriment of less developed follicles (1, 2, 7) . Ovulation and luteinization are also characterized by remarkable changes in the vasculature, as capillary endothelial cells within the theca interna rapidly proliferate and invade the avascular granulosa cell layer of the follicle to form a capillary plexus (6, 8 -10) .
Vascular endothelial growth factor (VEGF), an endothelial-specific mitogenic, chemotactic, and permeability agent, is a key agent associated with rapid vascular growth in a variety of physiological and pathological conditions (11, 12) .
In situ hybridization and Northern analyses detected VEGF messenger ribonucleic acid (mRNA) expression within the dominant follicle and developing corpus luteum of both nonprimate (13) and primate (14, 15) species. Increased VEGF mRNA expression in the rat ovary after a bolus of hCG provides indirect evidence that VEGF production and secretion by periovulatory follicles is stimulated by the midcycle gonadotropin surge (16) . Additionally, decreased VEGF mRNA expression in the monkey corpus luteum (15) after the administration of a GnRH antagonist suggests that VEGF production is also dependent on tonic gonadotropin secretion during the ovarian cycle. Recently, VEGF was localized by immunocytochemistry to human granulosa cells in the preovulatory follicle and to luteal cells within the corpus luteum (17, 18) . However, studies directly examining VEGF production and its regulation by gonadotropins in granulosa/luteal cells of primate species have not been reported. The objectives of this study were 1) to determine whether macaque granulosa cells produce VEGF in response to an in vivo ovulatory surge of FSH-or LH/CG-like gonadotropins, and 2) to examine the direct effects of pure human (h) gonadotropins [i.e. recombinant hFSH (r-hFSH) and r-hLH] on VEGF production by preovulatory (nonluteinized) and periovulatory (luteinized) granulosa cells in culture. In addition, VEGF production was correlated with progesterone synthesis by granulosa cells.
Materials and Methods

Animals and follicular stimulation protocols
Rhesus monkeys (Macaca mulatta) were maintained at the Oregon Regional Primate Research Center as previously described (19) . Animal protocols were approved by the Oregon Regional Primate Research Center Animal Care and Use Committee, and studies were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Adult female monkeys exhibiting regular menstrual cycles (ϳ28 days) were checked daily for menses. Beginning at menses, monkeys received human gonadotropins to promote the development of multiple preovulatory follicles (20, 21) . In study 1, animals either received twice daily injections of urinary gonadotropins [30 IU hFSH, twice daily (Metrodin, Serono Laboratories, Norwell, MA) for 6 days followed by 30 IU hFSH and 30 IU hLH twice daily (Pergonal, Serono Laboratories) for 2-3 days] followed by no ovulatory stimulus or the standard ovulatory stimulus (1000 IU hCG; Profasi, Serono Laboratories; n ϭ 6/group) (20) , or monkeys received r-hFSH (30 IU, twice daily; Laboratoires Serono, Aubonne, Switzerland) for 12 days followed by a bolus of 100 or 1000 IU r-hCG (Laboratoires Serono) or 2500 IU r-hFSH (n ϭ 5/group) (21) . In study 2, monkeys received r-hFSH (30 IU, twice daily) for 6 days and r-hFSH (30 IU) plus r-hLH (30 IU) twice daily for 3 days followed by no ovulatory stimulus or 1000 IU of hCG (n ϭ 6/group). Monkeys in both studies received a GnRH antagonist, antide (1 mg/kg BW⅐day; Laboratoires Serono), throughout the follicular stimulation protocol to block endogenous secretion of pituitary gonadotropins (22) . Daily blood samples were obtained from unanesthetized animals by saphenous venipuncture from the beginning of gonadotropin treatment until 4 days after follicular aspiration. Serum estradiol or progesterone concentrations were determined by RIA (23, 24) . Follicular growth/maturation was monitored by serum estrogen levels and ultrasonography (22) . Baseline levels (Յ0.1 ng/mL) of serum progesterone in samples collected after follicle aspiration confirmed that animals receiving no ovulatory stimulus lacked an endogenous surge of pituitary gonadotropins.
Cell preparation and culture
Granulosa cells were obtained by follicle aspiration during laparoscopy of anesthetized animals (25) either the morning after the last FSH plus LH treatment (nonluteinized granulosa cells; NLGC) or 27 h after administration of the bolus of hCG and/or FSH (luteinized granulosa cells; LGC). After oocyte removal, enriched preparations of granulosa cells from individual monkeys were obtained as previously described (26) . Pooled follicular aspirates were centrifuged at 290 ϫ g for 10 min to obtain a cell pellet that was resuspended in Ham's F-10 medium (Life Technologies, Grand Island, NY) supplemented with penicillin G (20 mg/L), streptomycin sulfate (100 mg/L), sodium bicarbonate (1.2 g/L), HEPES buffer (4.7 g/L), and BSA (1 g/L; Sigma Chemical Co., St. Louis, MO), pH 7.4. The cell suspension was layered on a 40% Percoll (Sigma Chemical Co.) and 60% Hanks' Balanced Salt Solution containing 0.1% BSA and centrifuged at 470 ϫ g for 30 min (26) . The resulting layer of granulosa cells was resuspended in culture medium, cell numbers were determined using a hemocytometer, and cell viability was assessed by trypan blue exclusion.
In study 1, granulosa cells collected after the urinary hFSH plus hLH stimulation protocol were plated on fibronectin (Sigma)-coated eightwell glass chamber slides (Nunc, Naperville, IL) at 8 ϫ 10 4 cells/well and cultured in DMEM-Ham's F-12 plus ITSA [insulin (2 mg/L), transferrin (5 mg/L), H 2 SeO 3 (0.25 nmol), and aprotinin (25 g/L); Sigma] medium containing 25 g/mL human low density lipoprotein (Sigma) (26) . Granulosa cells collected after the r-hFSH stimulation protocol were plated at 5 ϫ 10 4 cells/well in 48-well plastic plates and cultured in Ham's F-10 medium and 10% amenorrheic monkey serum (AMS) (21) . In both cases, granulosa cells were incubated at 37 C in a 5% CO 2 -95% air environment for 24 h in the presence and absence of 100 ng/mL hCG (CR123-NIH) (26) . Media were collected daily and frozen at Ϫ20 C until assayed for VEGF and progesterone. Cells were cultured in triplicate for each treatment group, and each experiment used a cell preparation from one monkey.
In study 2, granulosa cells were plated at 8 ϫ 10 4 cells/well on fibronectin-coated eight-well chamber slides and cultured in DMEMHam's F-12, ITSA, and 25 g/mL hLDL (i.e. control medium) for 6 days, with medium changed daily and frozen until assayed for VEGF and progesterone. Preparations of NLGC (n ϭ 3) and LGC (n ϭ 3) were cultured in control medium alone or in medium containing 0.1, 1, 10, and 100 ng/mL r-hFSH and r-hLH or 100 ng/mL hCG (CR-123). Again, in vitro treatments were tested in triplicate for each cell preparation (animal). To examine plating efficiency, cell proliferation, and the effects of combined LH and FSH treatment, additional groups of NLGC (n ϭ 3) and LGC (n ϭ 3) were cultured in control medium or in the presence of 100 ng/mL r-hFSH, r-hLH, hCG, and the combination of r-hFSH and r-hLH (100 ng/mL of each) for 4 days. Cells on slides 1 and 2 were methanol fixed on days 1 and 4 in preparation for determination of cell number via the crystal violet assay (26) .
Assays
VEGF concentrations in culture medium were quantitated by enzyme-linked immunosorbent assay (ELISA; Quantikine-human VEGF Immunoassay, R&D Systems, Minneapolis, MN). This highly specific sandwich assay recognizes human VEGF and exhibits negligible crossreactivity with more than 90 other cytokines/growth factors (R&D Systems). Our laboratory (27) and that of Shima et al. (28) demonstrated that rhesus and cynomolgus macaque VEGF mRNA encode for a protein that is 100% homologous to human VEGF (27) . A 96-well plate reader (Molecular Devices, Menlo Park, CA) set to read 450 nm emission was used to quantitate assay results. r-hVEGF (50 and 250 pg) was added to three different samples of spent culture medium, and recovery was 102%. To examine assay linearity, serial dilutions of samples were tested; correction for dilution of the culture medium indicated that the sample concentration had a coefficient of variation (CV) of less than 4%. We also compared Ham's F-10 and 10% AMS medium alone and with added VEGF. Ham's F-10 and 10% AMS contained no detectable VEGF, and the recovery averaged 95%. Standards included in each of the nine assays indicated that intra-and interassay CVs were 4.6% and 7.2%, respectively.
Basic fibroblast growth factor (bFGF) concentrations in culture medium were determined by ELISA (R&D Systems) for the control and 100 ng/mL r-hLH-treated cell cultures in study 2. The addition of bFGF to medium samples indicated that recovery was 97%, and serial dilution of three medium samples indicated that the assay was linear; the calculated CV for the dilutions was 8.9%. Medium progesterone concentrations were determined by RIA as previously validated in our laboratory (23) . The intra-and interassay CVs for the progesterone assay were 6.6% and 12.2%, respectively.
Statistical analyses
Statistical tests were performed using the Statpak (Northwest Analytical, Portland, OR) computer program. To correct for heterogeneity of variance as determined by Bartlett's test, log transformation of the VEGF (log X ), bFGF (log X ), and progesterone (1/log X ϩ 4) data was performed before analysis. In study 1, differences in medium VEGF and progesterone content were determined by two-way ANOVA, using a completely randomized split-plot design with animals assigned to in vivo treatments (main plots) and cells assigned to in vitro treatments (split plots). Unpaired t tests were used to detect differences between basal and hCG treatments within an in vivo treatment group (i.e. NLGC vs.
LGC). In study 2, VEGF, bFGF, and progesterone data were analyzed using a completely randomized split-split plot design, with animals assigned to the in vivo treatments (main plots) and the cells assigned to in vitro treatments (split plots) examined over days (split-split plots). r-hFSH and r-hLH dose responses were analyzed separately on days 1 and 4, using a completely randomized design with cells assigned to five different doses. After a significant (P Ͻ 0.05) F test, Duncan's multiple range tests were used to determine differences between means. All data are expressed as nontransformed values.
Results
Study 1: effects of an in vivo gonadotropin surge on VEGF production
VEGF production by nonluteinized and luteinized granulosa cells (i.e. NLGC and LGC) during short term incubations (24 h) in the presence and absence of hCG are depicted in Fig. 1 . Cells obtained from monkeys that did not receive an ovulatory stimulus (i.e. NLGC) produced approximately 8-fold lower (P Ͻ 0.05) levels of VEGF than cells from animals that received a standard gonadotropin bolus (1000 IU hCG; i.e. LGC) 27 h earlier to initiate periovulatory events. In vitro hCG treatment of NLGC increased (P Ͻ 0.05) VEGF 4-fold over control levels, to concentrations that were not different from LGC controls. In contrast, in vitro hCG treatment of LGC only modestly increased (P Ͻ 0.07) VEGF production compared to its control values. Progesterone levels produced by NLGC (55 Ϯ 13 ng/mL) also were much lower (P Ͻ 0.05) than those produced by LGC (519 Ϯ 177 ng/mL) under control conditions. In vitro hCG treatment markedly increased (P Ͻ 0.05) progesterone secretion by NLGC (16-fold), but only modestly increased that by LGC (1.5-fold; P Ͻ 0.05). As noted for VEGF levels, progesterone concentrations were not different between NLGC treated with hCG in vitro and LGC exposed to hCG in vivo and incubated under control conditions. Figure 2 depicts VEGF production by incubated granulosa cells obtained after different in vivo ovulatory stimuli (i.e. 100 vs. 1000 IU r-hCG and 2500 IU r-hFSH). VEGF synthesis by cells from monkeys that received a 10-fold lower dose (100 IU) of hCG was similar to that by cells from animals receiving the standard ovulatory bolus (1000 IU hCG). Furthermore, comparison of VEGF levels produced by LGC after in vivo exposure to 1000 IU r-hCG (Fig. 2 ) or urinary hCG (Fig. 1 ) indicated no differences. Cells obtained from monkeys that received a bolus of r-hFSH (2500 IU) also produced similar VEGF levels under control conditions as LGC obtained after a hCG bolus. In vitro hCG treatment increased (P Ͻ 0.05) VEGF production by cells collected after all three in vivo ovulatory stimuli compared to their respective control values. Progesterone production after all three ovulatory stimuli was not different and averaged 801 Ϯ 166 ng/mL when incubated in control medium. In vitro hCG treatment increased (P Ͻ 0.05) progesterone production for all groups and averaged 1726 Ϯ 443 ng/mL. Figure 3 depicts VEGF (A) and progesterone (B) levels produced by NLGC cultured for 6 days with or without (control) 100 ng/mL of various gonadotropins. Cells cultured in control medium had low levels of VEGF (140 Ϯ 34 pg/mL) on day 1, which declined (P Ͻ 0.05) progressively to nondetectable levels (Ͻ15 pg/mL) by day 5 of culture. rhFSH, r-hLH, and hCG markedly increased (P Ͻ 0.05) VEGF production above that observed in control medium alone throughout the culture interval. No significant differences were observed among the three gonadotropin treatments. Gonadotropin exposure progressively increased VEGF concentrations from day 1 through days 4 -5 of culture; levels remained at this level through day 6. Progesterone production by NLGC in the presence and absence of gonadotropins exhibited a pattern similar to that observed for VEGF. NLGC treated with a combination of 100 ng/mL FSH and LH produced levels of VEGF and progesterone not different from those elicited by either gonadotropin alone (data not shown). Figure 4 depicts VEGF and progesterone production by LGC during 6 days of culture in the presence or absence of 100 ng/mL of various gonadotropins. VEGF levels (Fig. 4A ) produced under control conditions were high and did not change throughout culture. Treatment with r-hFSH or rhLH, but not hCG, increased (P Ͻ 0.05) VEGF concentrations on day 1 of culture. Thereafter, VEGF levels produced by r-hFSH-, r-hLH-, and hCG-treated LGC were not different FIG. 1. VEGF production by granulosa cells obtained from large antral follicles of rhesus monkeys that either did not (nonluteinized; n ϭ 6) or did (luteinized; n ϭ 6) receive the standard ovulatory dose of 1000 IU hCG 27 h before follicle aspiration. Cells were incubated for 24 h in chemically defined medium without (control) or with 100 ng/mL hCG. a and b, Means Ϯ SEM with unlike superscripts are different (P Ͻ 0.05). from each other and were 3-to 4-fold greater than (P Ͻ 0.05) control levels. Progesterone concentrations (Fig. 4B ) in control cultures averaged 473 ng/mL over the first 4 days of culture before declining (P Ͻ 0.05) to 63 ng/mL on days 5-6. On day 1, r-hLH and r-hFSH, but not hCG, treatment increased (P Ͻ 0.05) progesterone levels compared to those in control medium. On days 2-6, all three gonadotropin treatments increased (P Ͻ 0.05) progesterone concentrations to a similar extent compared to control values. LGC treated with both 100 ng/mL FSH and LH produced levels of VEGF and progesterone not different from those elicited by either gonadotropin alone (data not shown).
Study 2: effects of in vitro gonadotropin exposure on VEGF production
Comparison of the changes in VEGF and progesterone synthesis by NLGC after 4 days of culture with various doses of r-hLH is summarized in Fig. 5 . r-hLH caused a dosedependent increase (P Ͻ 0.05) in VEGF and progesterone production by NLGC, with the lowest dose (0.1 ng/mL)
FIG. 4. VEGF (A) and progesterone (B)
production by luteinized granulosa cells obtained from rhesus monkeys (n ϭ 3) that received an ovulatory dose of hCG. Cells were cultured as described in Fig. 3 . The common estimate of variances for VEGF and progesterone (defined as ͱMSE/n, where MSE is the mean square error from ANOVA of all data in a treatment group) were determined for control (56 pg/mL and 140 ng/mL), r-hFSH (142 and 154), r-hLH (154 and 407), and hCG (217 and 446) treatment groups. *, Daily means for VEGF and progesterone production by control cells were different (P Ͻ 0.05) from the those for production by r-hFSH-, r-hLH-, and hCG-treated cells on specified days. All gonadotropin-treated cells exhibited similar VEGF and progesterone levels. #, Mean VEGF and P concentrations for the r-hFSH and r-hLH treatment groups were greater (P Ͻ 0.05) than control levels on day 1. a, Mean VEGF concentrations for the hCG-treated cells increased (P Ͻ 0.05) between days 1 and 3 of culture. b-e, Mean progesterone concentrations within a treatment group (e.g. control) with unlike superscripts are different (P Ͻ 0.05) across days.
FIG. 3. Levels of VEGF (A) and progesterone (B)
produced by nonluteinized granulosa cells obtained from rhesus monkeys (n ϭ 3) not receiving an ovulatory dose of hCG. Granulosa cells were cultured for 6 days in chemically defined medium without (control) or with 100 ng/mL r-hFSH, r-hLH, or hCG. The common estimates of variance for VEGF and progesterone (defined as ͱMSE/n, where MSE is the mean square error from ANOVA of all data in a treatment group) were determined for control (17 pg/mL and 6 ng/mL), r-hFSH (593 and 405), r-hLH (145 and 359), and hCG (138 and 349) treatment groups. *, Daily means for VEGF and progesterone production by control cells were different (P Ͻ 0.05) from those for production by the r-hFSH-, r-hLH-, and hCG-treated cells across all days. r-hFSH-, r-hLH-, and hCG-treated cells exhibited similar VEGF and progesterone levels. a-d, Means within a treatment group (e.g. r-hFSH) with unlike superscripts are different (P Ͻ 0.05) across days. eliciting no effect and the remaining doses producing elevated levels compared to control values. On day 1 of culture, similar dose-response curves for VEGF and progesterone production by NLGC were observed, except the relative stimulation by r-hLH was lower than that on day 4 (data not shown). In contrast, when LGC were cultured with various doses of r-hLH, only the highest concentrations increased VEGF (100 ng/mL; P Ͻ 0.05; data not shown; see Fig. 4 ) or progesterone (10 or 100 ng/mL; P Ͻ 0.05; data not shown) levels on day 1 or 4.
Comparison of the changes in VEGF and progesterone synthesis by NLGC after 4 days of culture with various doses of r-hFSH is depicted in Fig. 6 . Low doses (0.1 and 1 ng/mL) of r-hFSH did not enhance VEGF levels, whereas the 10 and 100 ng/mL doses markedly increased (P Ͻ 0.05) VEGF concentrations. Progesterone levels increased (P Ͻ 0.05) slightly in response to 1 ng/mL r-hFSH, whereas the 10 and 100 ng/mL doses elicited a large increase (P Ͻ 0.05). NLGC exhibited similar dose-response curves for VEGF and progesterone production on day 1 of culture, with the only difference being that the relative stimulation by r-hFSH was lower (data not shown) than that on day 4. In contrast, LGC production of VEGF and progesterone on days 1 and 4 only increased (P Ͻ 0.05) in response to the highest (100 ng/mL) dose of r-hFSH (data not shown; see Fig. 4 ).
Medium concentrations of bFGF were low and did not differ between NLGC and LGC throughout culture; therefore, the results are presented as combined data. bFGF concentrations for granulosa cells cultured in control medium were similar on days 1 and 2 (30.5 Ϯ 9.2 and 22.2 Ϯ 6.4 pg/mL), but declined (P Ͻ 0.05) progressively on days 3 and 4 of culture (14.8 Ϯ 4.9 and 8.0 Ϯ 1.6 pg/mL). LH-treated granulosa cells exhibited a similar decline in bFGF levels between days 2-4 of culture. However, inclusion of LH in the medium of either the NLGC or LGC cultures caused a 40 Ϯ 5% decline (P Ͻ 0.05) in bFGF concentrations compared to control values on the same day. Medium bFGF concentrations were below assay sensitivity (5 pg/mL) by days 5 and 6 of culture for both control and LH-treated cells. Figure 7 depicts the results of crystal violet assays that give an index (i.e. absorbance) of NLGC and LGC number on days 1 and 4 of culture. Absorbance values on day 1 were lower (P Ͻ 0.05) for NLGC than LGC, suggesting less adherence of NLGC to the fibronectin-coated slides. The absorbance (i.e. cell number) for NLGC did not change from day 1 to day 4 of culture for any treatment group. The absorbance for LGC cultured in control medium alone also did not differ between days 1 and 4. In contrast, LGC cultured in the presence of 100 ng/mL gonadotropins (i.e. r-hFSH, r-hLH, and hCG) had a 1.5-fold greater absorbance (i.e. cell number) compared to the control value.
FIG. 5. Dose-response curves for VEGF and progesterone production by nonluteinized granulosa cells after 4 days of culture with various concentrations of r-hLH. Cells were cultured as described in Fig. 3 . The common estimates of variance for VEGF and progesterone (defined as ͱMSE/n, where MSE is the mean square error from ANOVA and n ϭ 3) were 554 pg/mL and 321 ng/mL, respectively. a and b, Mean VEGF concentrations with unlike superscripts are different (P Ͻ 0.05). x and y, Mean progesterone concentrations with unlike superscripts are different (P Ͻ 0.05).
FIG. 6. Dose-response curves for VEGF and progesterone production by nonluteinized granulosa cells after 4 days of culture with various concentrations of r-hFSH. Cells were cultured as described in Fig. 3 . The common estimates of variance for VEGF and progesterone (defined as ͱMSE/n, where MSE is the mean square error from ANOVA and n ϭ 3) were 916 pg/mL and 336 ng/mL, respectively. a and b, Mean VEGF concentrations with unlike superscripts are different (P Ͻ 0.05). x-z, Mean progesterone concentrations with unlike superscripts are different (P Ͻ 0.05).
FIG. 7. Number of (absorbance) nonluteinized and luteinized granulosa cells after 1 and 4 days of culture in chemically defined medium without (control) or with 100 ng/mL r-hFSH, r-hLH, or hCG. Cells were cultured as described in Fig. 3 and fixed by methanol exposure after 1 or 4 days of culture. Nonluteinized and luteinized granulosa cell numbers (absorbance) were different (P Ͻ 0.05). a and b, Means Ϯ SEM with unlike superscripts are different (P Ͻ 0.05).
Discussion
This study is the first to demonstrate that primate granulosa cells from large antral follicles synthesize and secrete VEGF in response to an ovulatory bolus of either FSH-or LH/CG-like gonadotropins. Monkey granulosa cells obtained before an ovulatory surge of gonadotropins produced low levels of VEGF; however, levels increased about 8-fold after in vivo administration of either 1000 IU urinary or r-hCG [i.e. a standard ovulatory stimulus during in vitro fertilization (IVF)-related cycles in monkeys (20 -22) ]. Likewise, Kamat et al. (17) noted that immunocytochemical staining for VEGF in human granulosa-lutein cells of the developing corpus luteum was markedly increased compared to that in granulosa cells of the preovulatory follicle during the menstrual cycle. Recent studies of PMSG-treated rats also demonstrated that VEGF mRNA levels in the follicle were maximally stimulated (i.e. ϳ5-fold higher) within 4 h of hCG treatment (16) . Collectively, the data suggest an important role for the gonadotropin surge in mammalian species to stimulate an early increase in VEGF production, which may be important for follicle rupture and/or luteinization.
Our studies also demonstrated that a low dose (100 IU) was as effective as the standard ovulatory bolus (1000 IU) of r-hCG in enhancing VEGF production by granulosa cells. The data support other observations by this laboratory (21) that a 10-fold lower dose of hCG is sufficient to initiate follicular processes associated with oocyte maturation (e.g. reinitiation of meiosis) and luteinization of the granulosa cells (i.e. increased progesterone production). Thus, the levels of LH/CG required to stimulate many periovulatory events, including VEGF production by LGCs, may be less than the surge levels achieved in natural or IVF-related cycles. However, monkeys receiving 100 IU r-hCG had shorter luteal phases than animals receiving a standard ovulatory dose (21) . It is postulated that luteal phase defects (e.g. a short luteal phase) can result from inadequate vascularization of the corpus luteum (11) . It is possible that the lower hCG dose did not fully luteinize the cells, or only a subset of cells within the follicle(s) luteinized. Indeed, the pronounced rise in VEGF production by cells from the low (100 IU) group in response to in vitro hCG treatment was similar to the large increase observed with NLGC and contrasts to the minimal response observed with luteinized granulosa cells collected after the standard (1000-IU) bolus. Moreover, NLGC lost their ability to produce VEGF during culture if gonadotropins were not present, whereas LGC cultured in the absence of gonadotropins maintained elevated VEGF levels. These studies suggest an initial dependence on increased, if not surge (21) , levels of LH/CG for the establishment of appreciable VEGF synthesis that is lost (i.e. independent of gonadotropins) after luteinization of the granulosa cells.
This study is also the first to show that hCG and hLH directly stimulate VEGF production and secretion by primate granulosa cells. The large increase (ϳ5-fold) in VEGF synthesis by NLGC after in vitro hCG treatment was previously observed for progesterone production (29) and is probably due to gonadotropin binding to unoccupied LH receptors induced by the follicular stimulation protocol. In contrast, hCG or hLH treatment was not as effective in increasing VEGF synthesis by LGC; this attenuated response can be attributed to the higher basal VEGF levels, LH/CG receptor desensitization, or the lack of unoccupied receptors after in vivo exposure to a large bolus of hCG. The latter is supported by the results of study 1, in which a more pronounced response to in vitro hCG treatment was observed with cells collected from the low hCG (100 IU) and FSH treatment groups, than from the high (1000 IU) hCG treatment group. Human (30) and bovine (31) granulosa cells cultured in the presence of hCG/LH also increased VEGF mRNA expression. In contrast, rat granulosa cells cultured with LH did not respond with increased VEGF mRNA expression, even though in vivo hCG treatment was a highly effective inducer of VEGF mRNA (16) . Interestingly, these researchers observed that decreasing oxygen tension elevated VEGF mRNA expression by rat granulosa cells (32) . This lack of an LH/CG effect may be intrinsic to the immature rat model (i.e. the granulosa cells may not reach the appropriate maturational state to respond to LH) (16) , or it may indicate a species difference with regard to VEGF regulation or action within the ovary.
Recombinant hFSH, either administered in vivo as an ovulatory bolus (2500 IU) or added to cultures in high (10 -100 ng/mL) doses also stimulated VEGF production by granulosa cells. This laboratory reported recently that a bolus of r-hFSH was as effective as the standard bolus of hCG in eliciting periovulatory events (e.g. reinitiation of oocyte meiosis and luteinization of granulosa cells) during IVF-related cycles in monkeys (33) . These observations are consistent with the concept arising from rodent models (34, 35) that the midcycle FSH surge can play a role with (or substitute for) the LH surge to initiate periovulatory events, including VEGF production by granulosa cells. Our data appear to contrast somewhat with those reported by Neulen et al. (30) of no effect of a single dose (1 IU/mL) of FSH on VEGF mRNA expression by human luteinized granulosa cells from women. However, we observed a much greater response to FSH by NLGC than LGC in macaques. This difference could be related to measurement of VEGF mRNA vs. protein or to the presence of nonluteinized cells within the LGC preparation pooled from macaque follicles.
Earlier studies of angiogenesis in the ovary focused on bFGF, as this factor plays a critical role in a variety of tissues and is present in the developing corpus luteum (10, 32) . However, bFGF concentrations in medium from NLGC and LGC cultures in our study were extremely low and did not increase after either in vivo or in vitro gonadotropin treatment. In fact, in vitro LH treatment caused a significant decline in bFGF levels in culture medium. The apparent lack of bFGF production, however, could be due to our inability to measure macaque bFGF that may have remained associated with the cells and extracellular matrix. Our evidence of VEGF secretion is particularly relevant because in vitro angiogenesis (chemotactic and proliferative) assays indicate that conditioned medium from cultures of follicular cells and luteal cells contains a releasable growth factor (10) . Nevertheless, luteinized cells may produce several angiogenic factors, as immunoneutralization studies demonstrated that antibodies to VEGF blocked 65% of the angiogenic activity within luteal cell-conditioned medium (36) , whereas bFGF antibodies eliminated 25% of the angiogenic activity (10, 36) .
Four isoforms of VEGF arise from a single gene through alternative splicing of the VEGF mRNA (11) . Although the VEGF ELISA used in our study recognizes all isoforms, we presume that the secreted forms of VEGF (i.e. VEGF 121 and VEGF 165) (11) account for the majority produced by macaque granulosa cells. However, additional studies will be required to elucidate the VEGF isoforms or related molecules (11) produced by granulosa/luteal cells and their regulation by gonadotropin and other factors.
Progesterone production by the NLGC was highly correlated with VEGF production throughout the culture period. It is possible that progesterone acts locally via steroid receptor activation to mediate hCG/LH-stimulated VEGF production; this pathway is necessary for ovulation and luteinization in both rodent (37) and primate (38) species. In the rat, blockade of progesterone production by administration of aminoglutethimide, a P450 side-chain cleavage inhibitor, also prevented VEGF mRNA expression (39) . Retinal pigment epithelial cells also produce greater levels of VEGF after exposure to progesterone (40) . Alternatively, we cannot rule out that VEGF affects progesterone synthesis or progesterone receptor expression in granulosa cells during the periovulatory interval.
After the onset of the ovulatory gonadotropin surge, the follicular microvasculature becomes highly permeable as a result of increased endothelial fenestrations as well as intracellular gaps between endothelial cells (3, 5) . Previous studies in a variety of species linked the ovulatory gonadotropin stimulus with the production of inflammatory mediators (e.g. histamine, eicosanoids, platelet-activating factor, and bradykinin) that were postulated to mediate the increase in capillary permeability (41) . VEGF should be included as a possible candidate, as a bolus of hCG increases VEGF secretion, and this factor is 5,000-to 50,000-fold more potent than histamine in increasing cell permeability (42, 43) . The increased VEGF production by LGC is also consistent with a role for VEGF in the angiogenic process within the corpus luteum. Additional studies are needed to elucidate the physiological role(s) of VEGF in the processes of follicular maturation, ovulation, and development of the corpus luteum.
